SK Biopharmaceuticals Co Ltd (326030) Stock Price & News

Why is 326030 up 5.62%?

Dive Deeper

326030:KRX

SK Biopharmaceuticals Co Ltd

₩73,300.00

+5.62%

(+3,900.00) 1D

Oct 16, 3:30:21 PM GMT+9 · KRW

All symbols

	Symbol	Price	Change	% Change

Generating top insights for 326030...

Open

₩69,300

High

₩74,800

Low

₩69,100

Mkt. cap

5.74T

Avg. vol.

106.19K

Volume

141.30K

P/E ratio

14.32

52-wk high

₩144,100

52-wk low

₩67,800

EPS

₩5,120

Shares outstanding

78.31M

No. of employees

246

Open

₩69,300

High

₩74,800

Low

₩69,100

Mkt. cap

5.74T

Avg. vol.

106.19K

Volume

141.30K

P/E ratio

14.32

52-wk high

₩144,100

52-wk low

₩67,800

EPS

₩5,120

Shares outstanding

78.31M

No. of employees

246

Related stocks

Samsung Biologics Co Ltd

News stories

From web sources and news partners

Yahoo Finance

53 minutes ago

The 10-Year Treasury Is Above 5% for the First Time in Almost 20 Years. History Says This Is How the S&P 500 Index Will Perform Over the Next 12 Months.

Crypto Briefing

30 minutes ago

Morgan Stanley ties S&P 500 growth to a $1.6 trillion AI spending wave

www.tokenpost.com

2 hours ago

S&P 500 Health Care Sector Rises 3% as CVS Gains 7.2%

MarketWatch

2 hours ago

These surprising stocks could be some of the biggest drivers of S&P 500 earnings growth

About SK Biopharmaceuticals Co Ltd

CEO-

Employees246

Founded1993

Headquarters-

SectorPharmaceutical industry

Websiteskbp.com

All values in KRW	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	191.73B	194.36B	227.89B	247.37B
Cost of goods sold	7.55B	14.95B	14.33B	15.02B
Cost of revenue	7.55B	14.95B	14.33B	15.02B
Research and development expenses	40.93B	51.85B	47.59B	49.66B
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	68.98B	77.42B	71.09B	81.28B
Operating expense	114.07B	133.13B	123.79B	135.29B
Total operating expenses	121.62B	148.08B	138.12B	150.30B
Operating income	70.11B	46.28B	89.77B	97.06B
Other non operating income	-8.46B	-7.51B	-5.78B	-5.76B
EBT including unusual items	62.11B	33.76B	99.98B	93.36B
EBT excluding unusual items	61.27B	36.66B	89.89B	89.81B
Income tax expense	-9.26B	-98.98B	-2.76B	8.30B
Effective tax rate	-14.90%	-293.19%	-2.76%	8.88%
Other operating expenses	1.37B	1.11B	2.22B	1.42B
Net income	74.14B	136.59B	105.16B	85.06B
Net profit margin	38.67%	70.28%	46.15%	34.39%
Earnings per share	-	-	-	-
Interest and investment income	1.88B	1.72B	1.68B	2.37B
Interest expense	-1.70B	-1.32B	-1.30B	-1.26B
Net interest expenses	179.24M	397.10M	380.91M	1.11B
Depreciation and amortization charges	2.23B	2.18B	2.19B	2.17B
EBITDA	74.11B	50.23B	93.70B	101.08B
Gain or loss from assets sale	10.55M	176.00M	-	1.00K

Ask anything